Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (DE:135A)
FRANKFURT:135A
Holding DE:135A?
Track your performance easily
135A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.13 - €3.17
Previous Close€1.45
Volume0.00
Average Volume (3M)1.50K
Market Cap
€52.85M
Enterprise Value€999.71K
Total Cash (Recent Filing)$73.04M
Total Debt (Recent Filing)$15.54M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 06, 2024EPS Estimate
-€0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,856,463
10 Day Avg. Volume0
30 Day Avg. Volume1,504
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)15.94
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
€6.94Price Target Upside380.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SCYNEXIS News
Bulls Say, Bears Say
Bulls Say
Financial PositionScynexis has more than two years’ worth of cash plus a $10M milestone payment to be received after the submission of clinical study reports.
Regulatory ApprovalScynexis gained FDA approval for Brexafemme (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (rVVC).
Strategic PartnershipsGlaxo acquired ibrexafungerp global rights for a substantial amount plus tiered royalties.
Bears Say
Financial AdjustmentGSK’s deal was amended, now worth less than $434 million, due to an adjustment of in sales milestones following IBX’s manufacturing issues.
Product RecallScynexis placed a temporary clinical hold and recalled Brexafemme tablets following a review by GSK of its manufacturing process that found a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for IBX.
Regulatory IssuesThere are clinical and commercial holds for ibrexa, stemming from possible beta-lactam contamination.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.55% Insiders
31.39% Mutual Funds
20.19% Other Institutional Investors
32.86% Public Companies and
Individual Investors
135A FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was €1.13 and its highest was €3.17 in the past 12 months.
What is SCYNEXIS’s market cap?
Currently, no data Available
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 06, 2024 which is in 46 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 08, 2024. The company reported -€0.271 earnings per share for the quarter, missing the consensus estimate of -€0.173 by -€0.097.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -€0.13.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 37,856,464 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -€0.271 in its last earnings report, missing expectations of -€0.173. Following the earnings report the stock price went up 1.841%.
Which hedge fund is a major shareholder of SCYNEXIS?
Among the largest hedge funds holding SCYNEXIS’s share is Scion Asset Management. It holds SCYNEXIS’s shares valued at N/A.
---
SCYNEXIS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.94 (380.56% Upside)
€6.94 (380.56% Upside)
Blogger Sentiment
Bullish
DE:135A Sentiment 80%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.17%
12-Months-Change
Fundamentals
Return on Equity
-46.12%
Trailing 12-Months
Asset Growth
-30.38%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
---
135A Company Deck
---
135A Earnings Call
Q4 2023
0:00 / 0:00
---
135A Stock 12 Month Forecast
Average Price Target
€6.94
▲(380.56% Upside)
Technical Analysis
SCYNEXIS
―
Adaptimmune Therapeutics
―
ADMA Biologics
―
Chimerix
―
Karyopharm Therapeutics
―
Best Analysts Covering 135A
1 Year
1 Year Success Rate
6/38 ratings generated profit
1 Year Average Return
-23.86%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -23.86% per trade.
---